Year-End Report 2013

Reporting period January – December

  · Order intake rose 4.0% to SEK 25,395 M (24,416) and grew organically by 4.0%
  · Net sales increased 4.3% to SEK 25,287 M (24,248), corresponding to organic
growth of 4.2%
  · Profit before tax declined 8.2% to SEK 3,153 M (3,436)
  · Net profit decreased 9.3% to SEK 2,295 M (2,531)
  · Earnings per share declined 9.4% to SEK 9.59 (10.58)
  · EBITA before restructuring decreased 1.7% to SEK 4,766 M (4,849).
Adjusted for exchange-rate effects and the medical device tax introduced in the
US, EBITA rose 8.3%
  · A dividend per share of SEK 4.15 (4.15) is proposed, corresponding to SEK
989 M (989)

Reporting period October – December

  · Order intake rose 4.2% to SEK 6,931 M (6,648), and grew organically by 5.9%
  · Net sales declined 0.8% to SEK 7,757 M (7,816), corresponding to organic
growth of 1.3%
  · Profit before tax increased 18.1% to SEK 1,709 M (1,447)
  · EBITA before restructuring increased 6.1% to SEK 2,062 M (1,943). Adjusted
for exchange-rate effects and the medical device tax introduced in the US, EBITA
rose 14.0%
  · The acquisition of Pulsion Medical Systems is expected to be completed in
the first quarter of 2014

Order intake

The Group’s order intake posted a favorable trend for the quarter and grew
organically by 5.9%. Accordingly, for the full-year 2013, order intake increased
organically by 4.0%, a figure that compares favorably with other global medical
technology companies.